A live, programmable microbiota therapeutic disables virulence in gut pathogens

IF 26.8 1区医学 Q1 ENGINEERING, BIOMEDICAL

Nature Biomedical Engineering Pub Date : 2025-07-21 DOI:10.1038/s41551-025-01452-2

引用次数: 0

Abstract

Treatment of severe gastrointestinal illness caused by Shiga-toxin-producing enteropathogenic bacteria is a growing challenge owing to increasing antimicrobial resistance. We engineered a conjugative CRISPR-associated transposase to insert a genetic payload that inactivates the Shiga toxin gene of Enterobacteriaceae pathogens in the gut, establishing a foundation for microbial gene therapy.

Abstract Image

查看原文本刊更多论文

一种活的、可编程的微生物群治疗性地使肠道病原体丧失毒性

由于抗菌素耐药性日益增加，治疗由产志贺毒素肠致病菌引起的严重胃肠道疾病是一项日益严峻的挑战。我们设计了一种结合的crispr相关转座酶，在肠道中插入一种基因有效载荷，使肠杆菌科病原体的志贺毒素基因失活，为微生物基因治疗奠定了基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Biomedical Engineering Medicine-Medicine (miscellaneous)

CiteScore

45.30

自引率

1.10%

发文量

138

期刊介绍： Nature Biomedical Engineering is an online-only monthly journal that was launched in January 2017. It aims to publish original research, reviews, and commentary focusing on applied biomedicine and health technology. The journal targets a diverse audience, including life scientists who are involved in developing experimental or computational systems and methods to enhance our understanding of human physiology. It also covers biomedical researchers and engineers who are engaged in designing or optimizing therapies, assays, devices, or procedures for diagnosing or treating diseases. Additionally, clinicians, who make use of research outputs to evaluate patient health or administer therapy in various clinical settings and healthcare contexts, are also part of the target audience.